Hexagon Bio
Monday, June 03, 2024
Company Presentation
Oncology
Company Presentation Theater 1
Hexagon Bio's platform discovers novel targeted small molecules as payloads for antibody-drug conjugates (ADCs). Payload mechanisms of action are distinct from existing ADC payload mechanisms. Hexagon payload mechanisms include protein translation, which address cancer types not addressable by existing ADCs. Hexagon ADCs with novel payloads target TROP2 and HER2, addressing cancer types including breast, bladder, lung, gastroesophageal, and other cancers. Preclinical stage.
Company Website:
https://www.hexagonbio.com/
Lead Product in Development:
Preclinical. Antibody-drug conjugates (ADCs) in oncology:
Anti-TROP2 with novel payloads.
Anti-HER2 with novel ADC payloads.
Breast, bladder, lung, gastroesophageal, other cancers.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Company HQ City
Menlo Park
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Maureen Hillenmeyer
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())